NO20063768L - 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer - Google Patents

1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer

Info

Publication number
NO20063768L
NO20063768L NO20063768A NO20063768A NO20063768L NO 20063768 L NO20063768 L NO 20063768L NO 20063768 A NO20063768 A NO 20063768A NO 20063768 A NO20063768 A NO 20063768A NO 20063768 L NO20063768 L NO 20063768L
Authority
NO
Norway
Prior art keywords
thieno
pyrazole derivatives
kinase inhibitors
derivatives useful
useful
Prior art date
Application number
NO20063768A
Other languages
English (en)
Inventor
Mario Varasi
Daniele Fancelli
Paola Vianello
Simona Bindi
Sergio Vioglia
Dania Tesei
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Publication of NO20063768L publication Critical patent/NO20063768L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet tieno[2,3-c]pyrazolderivater med formel (I) og farmasøytisk akseptable salter derav, som definert i beskrivelsen, fremgangsmåte for fremstilling av dem og farmasøytiske preparater omfattende dem; forbindelsene ifølge oppfinnelsen kan være anvendelige ved terapi, ved behandling av sykdommer forbundet med en feilregulert proteinkinaseaktivitet, så som kreft.
NO20063768A 2004-02-03 2006-08-23 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer NO20063768L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54145204P 2004-02-03 2004-02-03
PCT/EP2005/001021 WO2005074922A1 (en) 2004-02-03 2005-02-02 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
NO20063768L true NO20063768L (no) 2006-11-02

Family

ID=34837492

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063768A NO20063768L (no) 2004-02-03 2006-08-23 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer

Country Status (38)

Country Link
US (2) US8138217B2 (no)
EP (1) EP1711177B1 (no)
JP (1) JP4908233B2 (no)
KR (1) KR20060124734A (no)
CN (1) CN1946395B (no)
AP (1) AP2006003701A0 (no)
AR (1) AR047531A1 (no)
AT (1) ATE396724T1 (no)
AU (1) AU2005210114B2 (no)
BR (1) BRPI0507375A (no)
CA (1) CA2555262C (no)
CR (1) CR8546A (no)
CY (1) CY1108246T1 (no)
DE (1) DE602005007181D1 (no)
DK (1) DK1711177T3 (no)
DO (1) DOP2005000014A (no)
EA (1) EA011032B1 (no)
EC (1) ECSP066767A (no)
ES (1) ES2307144T3 (no)
GE (1) GEP20094633B (no)
GT (1) GT200500020A (no)
HK (1) HK1101343A1 (no)
IL (1) IL177141A0 (no)
MA (1) MA28429B1 (no)
MX (1) MXPA06008787A (no)
NO (1) NO20063768L (no)
NZ (1) NZ548896A (no)
PA (1) PA8622801A1 (no)
PE (1) PE20051095A1 (no)
PL (1) PL1711177T3 (no)
PT (1) PT1711177E (no)
SI (1) SI1711177T1 (no)
TN (1) TNSN06244A1 (no)
TW (1) TW200526204A (no)
UA (1) UA86223C2 (no)
UY (1) UY28738A1 (no)
WO (1) WO2005074922A1 (no)
ZA (1) ZA200606179B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533138B2 (ja) * 2002-07-25 2010-09-01 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての縮環ヘテロ環式ピラゾール誘導体
WO2007009898A1 (en) * 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
AU2006298563A1 (en) * 2005-10-06 2007-04-12 Merck & Co., Inc. Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as D-amino acid oxidase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE524177T1 (de) 2006-03-30 2011-09-15 Nerviano Medical Sciences Srl Verwendung eines kinasehemmers zur behandlung von bestimmten resistenten tumoren
EP2051981B1 (en) * 2006-05-31 2010-08-25 Nerviano Medical Sciences S.R.L. 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors
FR2904626B1 (fr) * 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
KR100923540B1 (ko) 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
CL2009001158A1 (es) * 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
AU2010229144B2 (en) * 2009-03-23 2012-07-12 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
JP6314128B2 (ja) * 2012-04-05 2018-04-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 新たなアルキル化剤
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
EP3717492B1 (en) * 2017-11-30 2023-05-24 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2015566B3 (es) 1986-02-19 1990-09-01 Duphar Int Res B V Nuevos compuestos tio que tienen actividad fungicida.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE60023012T2 (de) 1999-08-12 2006-07-20 Pharmacia Italia S.P.A. 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
MXPA03001169A (es) * 2000-08-10 2003-06-30 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
EP1345909A1 (en) 2000-11-27 2003-09-24 Pharmacia Italia S.p.A. Phenylacetamido-pyrazole derivatives and their use as antitumor agents
EP1379524A2 (en) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Chromane derivatives, process for their preparation and their use as antitumor agents
IL160744A0 (en) 2001-09-26 2004-08-31 Pharmacia Italia Spa Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
CA2486101C (en) * 2002-05-17 2009-07-07 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ES2304531T3 (es) * 2002-07-17 2008-10-16 Pfizer Italia S.R.L. Derivados heterobiciclicos de pirazol como inhibidores de quinasa.
JP4533138B2 (ja) * 2002-07-25 2010-09-01 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての縮環ヘテロ環式ピラゾール誘導体
US20050026984A1 (en) * 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products

Also Published As

Publication number Publication date
CA2555262A1 (en) 2005-08-18
EA200601418A1 (ru) 2006-12-29
ES2307144T3 (es) 2008-11-16
TW200526204A (en) 2005-08-16
DK1711177T3 (da) 2008-09-29
EP1711177A1 (en) 2006-10-18
DE602005007181D1 (de) 2008-07-10
IL177141A0 (en) 2006-12-10
WO2005074922A1 (en) 2005-08-18
US8481584B2 (en) 2013-07-09
AR047531A1 (es) 2006-01-25
EA011032B1 (ru) 2008-12-30
CY1108246T1 (el) 2014-02-12
CR8546A (es) 2007-05-30
JP2007520513A (ja) 2007-07-26
TNSN06244A1 (fr) 2007-12-03
US8138217B2 (en) 2012-03-20
DOP2005000014A (es) 2006-08-15
ZA200606179B (en) 2008-02-27
ECSP066767A (es) 2006-11-24
KR20060124734A (ko) 2006-12-05
GT200500020A (es) 2005-09-06
US20120165311A1 (en) 2012-06-28
UY28738A1 (es) 2005-09-30
PE20051095A1 (es) 2005-12-31
MXPA06008787A (es) 2007-01-19
GEP20094633B (en) 2009-03-10
AU2005210114B2 (en) 2011-07-14
PL1711177T3 (pl) 2008-11-28
EP1711177B1 (en) 2008-05-28
CN1946395A (zh) 2007-04-11
MA28429B1 (fr) 2007-02-01
CN1946395B (zh) 2014-04-02
CA2555262C (en) 2014-10-14
NZ548896A (en) 2010-05-28
UA86223C2 (uk) 2009-04-10
BRPI0507375A (pt) 2007-07-10
PT1711177E (pt) 2008-09-04
AU2005210114A1 (en) 2005-08-18
PA8622801A1 (es) 2005-11-25
US20050187209A1 (en) 2005-08-25
JP4908233B2 (ja) 2012-04-04
AP2006003701A0 (en) 2006-08-31
ATE396724T1 (de) 2008-06-15
HK1101343A1 (en) 2007-10-18
SI1711177T1 (sl) 2008-10-31

Similar Documents

Publication Publication Date Title
NO20063768L (no) 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
WO2005005414A3 (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
PT1687305E (pt) Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
NO20072259L (no) Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
WO2008002245A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
WO2002012242A3 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
WO2004085436A3 (en) Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application